Drug Trial Radar · NCT04723810
TumorGlow Intraoperative Molecular Imaging (IMI)
Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Aug 14, 2024
Primary completion
Jan 14, 2027
Study completion Jan 14, 2027
Sponsor
- Lead sponsor
- University of PennsylvaniaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 study in patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment who are considered to be good surgical candidates to evaluate the safety and efficacy of the image-guided surgery using indocyanine green for intramolecular imaging of solid tumors.
Conditions
- Tumor, Solid
Interventions
Indocyanine GreenDrug
The investigational drug is indocyanine green, single dose between 1-5 mg/kg diluted into sterile water for intravenous (IV) injection up to 5 days prior to resection surgery. The actual dose and timing from dose to imaging will be determined based on tumor type.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: Determine the safety of indocyanine green (all tumor types combined)Time frame: Up to 5 days
- Cohort 1: Identify optimal dosing of indocyanine green before surgery, and camera combination (tumor type-specific)Time frame: Up to 5 days
- Cohort 1: Identify optimal timing of indocyanine green before surgery, and camera combination (tumor type-specific)Time frame: Up to 5 days
- Cohort 2: Determine the sensitivity and specificity of indocyanine green (tumor type-specific)Time frame: Up to 5 days
- Cohort 2: Confirm the efficacy of indocyanine green used with Near Infrared (NIR) fluorescent imaging as measured by Clinically Significant Event (CSE) rate (tumor type-specific)Time frame: Up to 5 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.